Figure 2 shows projected survival over 15 years for contemporary patients with PSA screen-diagnosed prostate cancer managed conservatively, using the central model assumptions (based on data from Albertsen et al (1998), with 100% attendance at biennial screening and multipliers for λO and γ of 0.25 and 1.15, respectively). This evidence concerns the gene KLK3 and prostate carcinoma.